Literature DB >> 10874210

Three new regions on chromosome 17p13.3 distal to p53 with possible tumor suppressor gene involvement in lung cancer.

E Tsuchiya1, A Tanigami, Y Ishikawa, K Nishida, M Hayashi, Y Tokuchi, T Hashimoto, S Okumura, S Tsuchiya, K Nakagawa.   

Abstract

We investigated loss of heterozygosity (LOH) at the distal portion of the p53 gene on the short arm of chromosome 17 in lung cancers in order to search for new tumor suppressor genes. The roles of the putative genes were also studied in terms of pathological features. One hundred and forty-five resected non-small cell lung cancers were examined for LOH using 11 markers mapped on, and distal to the p53 locus, and deletion maps were constructed. Four commonly deleted regions were found: one from TP53 to ENO3, where the p53 gene resides, and three others from ENO3 to D17S1566, D17S379 to D17S1574 and distal to ABR, with LOH frequencies almost the same as, or higher than, at the TP53 locus. Examination of the relationship between LOH of the latter three regions and histopathological parameters of adenocarcinomas (genetically negative for p53 mutation) revealed allelic losses on D17S379 to be associated with advanced lesions, while D17S513 was more frequently deleted in poorly differentiated tumors. These results indicate that new tumor suppressor gene(s) may reside on these three distinctly deleted regions on chromosome 17p13.3 distal to the p53 gene in lung cancer, with possible roles in progression and differentiation of adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874210      PMCID: PMC5926396          DOI: 10.1111/j.1349-7006.2000.tb00986.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  30 in total

1.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.

Authors:  V Esposito; A Baldi; A De Luca; A M Groger; M Loda; G G Giordano; M Caputi; F Baldi; M Pagano; A Giordano
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

2.  Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers.

Authors:  H Konishi; T Takahashi; K Kozaki; Y Yatabe; T Mitsudomi; Y Fujii; T Sugiura; H Matsuda; T Takahashi; T Takahashi
Journal:  Oncogene       Date:  1998-10-22       Impact factor: 9.867

3.  Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung.

Authors:  S Sato; Y Nakamura; E Tsuchiya
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

4.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.

Authors:  M M Wales; M A Biel; W el Deiry; B D Nelkin; J P Issa; W K Cavenee; S J Kuerbitz; S B Baylin
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

5.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.

Authors:  J W Harbour; S L Lai; J Whang-Peng; A F Gazdar; J D Minna; F J Kaye
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

6.  Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas.

Authors:  N Hayashi; Y Sugimoto; E Tsuchiya; M Ogawa; Y Nakamura
Journal:  Biochem Biophys Res Commun       Date:  1994-08-15       Impact factor: 3.575

Review 7.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

8.  Identification of two candidate tumor suppressor genes on chromosome 17p13.3.

Authors:  D C Schultz; L Vanderveer; D B Berman; T C Hamilton; A J Wong; A K Godwin
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

9.  Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor.

Authors:  G Meroni; A Reymond; M Alcalay; G Borsani; A Tanigami; R Tonlorenzi; C Lo Nigro; S Messali; M Zollo; D H Ledbetter; R Brent; A Ballabio; R Carrozzo
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

10.  MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.

Authors:  M Higashiyama; O Doi; K Kodama; H Yokouchi; T Kasugai; S Ishiguro; K Takami; T Nakayama; I Nishisho
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  3 in total

1.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

2.  Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer.

Authors:  H Matsumoto; H Matsuyama; K Fukunaga; S Yoshihiro; T Wada; K Naito
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

3.  Expression and clinical significance of HCCS1 in non-small cell lung cancer.

Authors:  Shen Xiao-Yong; Lin Zhi-Feng; Lu Fan-Zhen; Ruan Zhen; Zhen Jian; Huang Hai-Long; Ju Chao-Qiang
Journal:  Contemp Oncol (Pozn)       Date:  2012-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.